UBS AM
ANIK icon

UBS AM’s Anika Therapeutics ANIK Stock Holding History

UBS AM’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-8,829
Closed -$210K – 2562
2022
Q3 		$210K Sell
8,829
-1,580
-15% -$36.4K ﹤0.01% 2594
2022
Q2 		$232K Sell
10,409
-8,829
-46% -$197K ﹤0.01% 2543
2022
Q1 		$483K Hold
19,238
– – ﹤0.01% 2476
2021
Q4 		$689K Hold
19,238
– – ﹤0.01% 2405
2021
Q3 		$819K Buy
19,238
+3,253
+20% +$134K ﹤0.01% 2269
2021
Q2 		$692K Sell
15,985
-558
-3% -$23.8K ﹤0.01% 2402
2021
Q1 		$675K Hold
16,543
– – ﹤0.01% 2273
2020
Q4 		$749K Hold
16,543
– – ﹤0.01% 2126
2020
Q3 		$585K Buy
16,543
+7,714
+87% +$279K ﹤0.01% 2067
2020
Q2 		$333K Sell
8,829
-6,955
-44% -$229K ﹤0.01% 2254
2020
Q1 		$456K Sell
15,784
-682
-4% -$27.6K ﹤0.01% 2008
2019
Q4 		$854K Buy
16,466
+633
+4% +$36.8K ﹤0.01% 1993
2019
Q3 		$869K Buy
15,833
+9,198
+139% +$472K ﹤0.01% 2022
2019
Q2 		$270K Buy
+6,635
New +$242K ﹤0.01% 2443
2018
Q2 		– Sell
-33
Closed -$1.64K – 2783
2018
Q1 		$1.64K Hold
33
– – ﹤0.01% 2636
2017
Q4 		$1.78K Hold
33
– – ﹤0.01% 2555
2017
Q3 		$1.91K Hold
33
– – ﹤0.01% 2506
2017
Q2 		$1.63K Buy
+33
New +$1.52K ﹤0.01% 2491
2016
Q4 		– Sell
-5,500
Closed -$263K – 2503
2016
Q3 		$263K Hold
5,500
– – ﹤0.01% 2333
2016
Q2 		$295K Hold
5,500
– – ﹤0.01% 2229
2016
Q1 		$246K Hold
5,500
– – ﹤0.01% 2317
2015
Q4 		$210K Buy
+5,500
New +$210K ﹤0.01% 2509
2015
Q2 		– Sell
-5,200
Closed -$214K – 2697
2015
Q1 		$214K Buy
+5,200
New +$210K ﹤0.01% 2455
2014
Q3 		– Sell
-4,800
Closed -$222K – 2561
2014
Q2 		$222K Buy
+4,800
New +$213K ﹤0.01% 2358

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

UBS AM's ANIK Position: Q4 2022 in Review

UBS AM sold out of Anika Therapeutics (ANIK) in Q4 2022, closing a stake of 8,829 shares — an estimated $210K sold.

UBS AM first reported a position in ANIK in Q2 2014 and held it in 24 quarters. The position peaked at $869K in Q3 2019. 123 funds tracked by Wall St. Rank hold ANIK as of Q4 2022.

  • UBS AM reported no remaining Anika Therapeutics position as of Q4 2022 after selling out during the quarter.
  • UBS AM sold 8,829 Anika Therapeutics shares in Q4 2022, an estimated $210K.
  • UBS AM first reported a position in Anika Therapeutics in Q2 2014 and held it in 24 quarters.
  • UBS AM's Anika Therapeutics position peaked at $869K in Q3 2019.
  • 123 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2022.

Based on UBS AM's 13F filing for Q4 2022, filed 14 Feb 2023.